Immuno-Oncology Treatments Finding Success with Combination Therapies

With oncology drugs clocking a disheartening 3.4% success rate, some good news in the field is always appreciated.

Bristol Myers Squibb combined approved Opdivo with anti-LAG-3 antibody relatlimab in RELATIVITY-047, a Phase II/III trial. The trial compared the combo to use of Opdivo alone in metastatic melanoma patients. The drug mashup met its primary goal for progression-free survival.